Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Prolexys Pharmaceuticals
* To determine the maximum tolerated dose (MTD) and the dose limiting toxicities (DLT) of PRLX 93936 administered IV 3 days a week (Monday, Wednesday and Friday) for 3 weeks followed by a 9 day rest period, as treatment for patients with relapsed or relapsed/refractory multiple myeloma. * To establish the dose of PRLX 93936 recommended for future studies. * To characterize potential toxicities of PRLX 93936. * To assess the pharmacokinetic profile of PRLX 93936. * To evaluate response to treatment, time to response (TTR) and duration of response. * To evaluate time to progression (TTP).
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted